Cerity Partners LLC Has $580,000 Stock Holdings in Privia Health Group, Inc. (NASDAQ:PRVA)

Cerity Partners LLC grew its holdings in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 122.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,821 shares of the company's stock after buying an additional 14,195 shares during the quarter. Cerity Partners LLC's holdings in Privia Health Group were worth $580,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bessemer Group Inc. raised its holdings in shares of Privia Health Group by 2,393.4% in the 1st quarter. Bessemer Group Inc. now owns 2,269 shares of the company's stock valued at $51,000 after purchasing an additional 2,178 shares during the period. GAMMA Investing LLC grew its position in shares of Privia Health Group by 113.1% during the 1st quarter. GAMMA Investing LLC now owns 2,866 shares of the company's stock worth $64,000 after purchasing an additional 1,521 shares in the last quarter. Financial Management Professionals Inc. lifted its holdings in shares of Privia Health Group by 28.7% during the 1st quarter. Financial Management Professionals Inc. now owns 3,383 shares of the company's stock worth $76,000 after acquiring an additional 754 shares during the period. Quadrant Capital Group LLC lifted its holdings in shares of Privia Health Group by 11.8% during the 4th quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock worth $95,000 after acquiring an additional 511 shares during the period. Finally, Neo Ivy Capital Management lifted its holdings in shares of Privia Health Group by 81.5% during the 4th quarter. Neo Ivy Capital Management now owns 6,540 shares of the company's stock worth $127,000 after acquiring an additional 2,936 shares during the period. 94.48% of the stock is owned by institutional investors.

Insider Transactions at Privia Health Group

In other news, CEO Parth Mehrotra sold 13,773 shares of the stock in a transaction on Monday, May 12th. The shares were sold at an average price of $24.99, for a total transaction of $344,187.27. Following the completion of the sale, the chief executive officer directly owned 423,143 shares in the company, valued at $10,574,343.57. This represents a 3.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO David Mountcastle sold 3,322 shares of the stock in a transaction on Monday, May 12th. The stock was sold at an average price of $24.99, for a total transaction of $83,016.78. Following the sale, the chief financial officer owned 172,909 shares of the company's stock, valued at approximately $4,320,995.91. This trade represents a 1.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 45,949 shares of company stock worth $1,100,368 over the last three months. 10.70% of the stock is owned by company insiders.

Privia Health Group Price Performance

Shares of PRVA traded down $0.01 during trading hours on Monday, hitting $19.70. 727,973 shares of the stock were exchanged, compared to its average volume of 871,792. Privia Health Group, Inc. has a fifty-two week low of $16.47 and a fifty-two week high of $26.09. The business has a 50-day moving average of $21.96 and a 200-day moving average of $22.97. The firm has a market capitalization of $2.40 billion, a P/E ratio of 164.18, a price-to-earnings-growth ratio of 3.15 and a beta of 0.82.

Wall Street Analyst Weigh In

Several brokerages recently commented on PRVA. Barclays increased their price objective on shares of Privia Health Group from $23.00 to $24.00 and gave the company an "equal weight" rating in a research note on Tuesday, May 27th. Truist Financial increased their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the company a "buy" rating in a research note on Thursday, April 10th. JPMorgan Chase & Co. increased their price objective on shares of Privia Health Group from $29.00 to $32.00 and gave the company an "overweight" rating in a research note on Wednesday, May 28th. Needham & Company LLC reissued a "buy" rating and issued a $30.00 price objective on shares of Privia Health Group in a research note on Thursday, April 10th. Finally, Robert W. Baird increased their price objective on shares of Privia Health Group from $24.00 to $26.00 and gave the company an "outperform" rating in a research note on Tuesday, April 15th. One equities research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $28.38.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.